Market Place
Sourcing Support
Galapagos announces first quarter 2023 financial results
04 May 2023 //
GLOBENEWSWIRE
Galapagos initiates Phase 3 program with filgotinib in patients with AAS
26 Apr 2023 //
GLOBENEWSWIRE
Galapagos announces results from PIII trial of filgotinib in Crohn’s disease
09 Feb 2023 //
PRESS RELEASE
EMA backs restrictions on certain immune-regulating drugs
12 Nov 2022 //
BIOPHARMADIVE
Galapagos announces strategy to accelerate innovation & reports 3Q 2022 results
04 Nov 2022 //
PRESS RELEASE
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
01 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns
29 Oct 2022 //
ENDPTS
Once daily JYSELECA ®(filgotinib) to be made available on the NHS
10 Oct 2022 //
PHARMIWEB
Jyseleca licensed for active ulcerative colitis in Great Britain
18 Jan 2022 //
GLOBENEWSWIRE
Jyseleca®?(filgotinib) approved in the European Union for the treatment
15 Nov 2021 //
GLOBENEWSWIRE
Galapagos Announces Positive CHMP Opinion for Jyseleca for Ulcerative Colitis
17 Sep 2021 //
GLOBENEWSWIRE
NHS in Scotland makes rheumatoid arthritis drug available
14 Sep 2021 //
PHARMAFILE
Galapagos announces departure of CSO Piet Wigerinck later this year
22 Jun 2021 //
GLOBENEWSWIRE
Galapagos reports long-awaited safety data for inflammation drug
04 Mar 2021 //
BIOPHARMADIVE
Galapagos posts a safety win for filgotinib, but is it too little, too late?;
04 Mar 2021 //
ENDPTS
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
21 Jan 2021 //
PHARMATIMES
NICE recommends rheumatoid arthritis drug Jyseleca for NHS use (Pharmafile)
21 Jan 2021 //
PHARMAFILE
Gilead guts its filgotinib plans—and CEO`s rebuild along with it
17 Dec 2020 //
FIERCE PHARMA
Gilead’s Dan O’Day pulls the plug on the lion’s share of their filgotinib
15 Dec 2020 //
ENDPTS
JYSELECA® (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN
18 Nov 2020 //
PRESS RELEASE
Gilead submits filgotinib to European regulators for UC; GW launches PhIII trial
03 Nov 2020 //
ENDPTS
EMA begins evaluation of filgotinib for ulcerative colitis
03 Nov 2020 //
PHARMATIMES
European Medicines Agency Validates Marketing Application for Filgotinib
02 Nov 2020 //
BUSINESSWIRE
Gilead hits the brakes on a trifecta of mid stage studies- troubled filgotinib
30 Oct 2020 //
ENDPTS
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance
13 Oct 2020 //
PRESS RELEASE
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance
12 Oct 2020 //
BUSINESSWIRE
Celltrion Initiates Post-exposure Prophylaxis Clinical Trial of an Anti-COVID-19
12 Oct 2020 //
BUSINESSWIRE
Gilead and Galapagos`s filgotinib shows sustained efficacy in ulcerative colitis
12 Oct 2020 //
SEEKINGALPHA
Gilead Sciences`s Jyseleca (Filgotinib) Receives Approval In Europe
01 Oct 2020 //
EMA
Gilead Sciences Ireland UC Jyseleca (Filgotinib) Receives Approval in Europe
30 Sep 2020 //
EMA
Gilead Sciences, Eisai receive Japanese approval for Jyseleca to treat RA
29 Sep 2020 //
PHARMABIZ
Gilead’s oral JAK inhibitor filgotinib wins EU approval
29 Sep 2020 //
PHARMATIMES
Gilead`s rheumatoid arthritis med filgotinib, wins global-first nod in Japan
26 Sep 2020 //
FIERCE PHARMA
Gilead and Galapagos` filgotinib OK`d in Europe for rheumatoid arthritis
25 Sep 2020 //
SEEKING ALPHA
Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis
24 Sep 2020 //
BUSINESSWIRE
Gilead shares slide after FDA knocks back rheumatoid arthritis drug
20 Aug 2020 //
REUTERS
FDA hands Gilead a stunning rejection for blockbuster RA candidate filgotinib
20 Aug 2020 //
ENDPTS
Gilead Receives Complete Response Letter for Filgotinib
19 Aug 2020 //
BUSINESSWIRE
EMA: Thumbs up for 11, down for 2 new medicines
25 Jul 2020 //
RAPS
Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca®
24 Jul 2020 //
BUSINESSWIRE
Gilead builds case for filgotinib in active psoriatic arthritis
09 Jun 2020 //
FIERCE BIOTECH
Filgotinib Demonstrates Durable Efficacy Consistent Safety Profile at 52 Weeks
04 Jun 2020 //
PRESS RELEASE
Filgotinib Demonstrates Durable Efficacy & Consistent Safety Profile at 52 Weeks
04 Jun 2020 //
BUSINESSWIRE
Gilead woos filgotinib clinical investigator from Stanford to lead the on NASH
02 Jun 2020 //
ENDPTS
Gilead`s filgotinib phase 3 hits goal but details dampen hopes
22 May 2020 //
FIERCE BIOTECH
Galapagos CEO talks next steps as coronavirus stalls the biotech`s top drug
26 Mar 2020 //
BIOPHARMADIVE
JPM: Gilead leans on data, focus to launch filgotinib into jam-packed RA market
20 Jan 2020 //
FIERCE PHARMA
Disappointing efficacy for ASIT Biotech`s pollen drug
04 Dec 2019 //
PHARMATIMES
New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy
11 Nov 2019 //
BUSINESSWIRE
Gilead’s filgotinib fails midphase tests in lupus, Sjogren`s
26 Oct 2019 //
FIERCE BIOTECH
Gilead`s ready to spend big on Descovy, filgotinib launches: CEO
24 Oct 2019 //
FIERCE PHARMA
Gilead elevates M&A architect Dickinson to CFO. Could more deals be next?
16 Oct 2019 //
FIERCE PHARMA
Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib
10 Oct 2019 //
BUSINESS WIRE
Chasing AbbVie, Gilead files for approval of filgotinib in Japan
09 Oct 2019 //
FIERCE BIOETCH
AbbVie`s Rinvoq label portends safety warnings for future JAKs
20 Aug 2019 //
FIERCE PHARMA
EMA accepts Gilead`s filgotinib application for rheumatoid arthritis
15 Aug 2019 //
SEEKINGAPLHA
Celgene’s Otezla, heading for selloff, nabs niche inflammation market
23 Jul 2019 //
FIERCE PHARMA
Gilead should nab Celgene`s Otezla, analysts say. Here`s why
19 Jul 2019 //
FIERCE PHARMA
Gilead inks $5B upfront deal to gain broad access to Galapagos` pipeline
16 Jul 2019 //
FIERCE BIOTECH
